Sickle Cell Diastolic Cardiomyopathy and Mortality Risk: A Novel Echocardiographic Framework for Prognostic Stratification

镰状细胞舒张性心肌病与死亡风险:一种用于预后分层的新型超声心动图框架

阅读:1

Abstract

Cardiovascular complications are the leading cause of mortality in sickle cell anemia (SCA) patients. While extensive data have identified diastolic dysfunction (DD) to increase morbidity and mortality, the unique hemodynamic conditions inherent to SCA challenge the current recommendations to assess diastolic function. Thus, there is an urgent need to refine the echocardiographic definition of DD to improve risk stratification and therapeutic strategies in SCA patients. We analyzed data from the French multicentric Etendard cohort and compared them with an age- and sex-matched control group from the Copenhagen City Heart Study (CCHS). We focused on left ventricular diastolic parameters, specifically lateral e' velocity (e' lat), E/e' ratio, and indexed left atrial volume (LAVi), assessing their association with clinical outcomes over a 12-year follow-up. Etendard SCA patients (n = 379) had an early impaired diastolic function compared to the CCHS controls (n = 672). This was particularly obvious in young SCA patients (n = 252, age ≤ 38 years) in whom e' lat was associated with prognosis (p = 0.01), with an optimal cut-off value below 11 cm/s. Indeed, young SCA patients with DD had a fourfold increased 12-year mortality rate as compared with SCA patients without DD (16 vs. 4%, p < 0.001). Additionally, e' lat correlated with 6-min walk test, NT pro-BNP levels, diastolic blood pressure, and lactate dehydrogenase levels. In young SCA patients, our data contribute to refine the diagnosis of diastolic dysfunction evaluation. We highlight the prognostic value below 11 cm/s of lateral e' velocity and its association with key contributors of cardiac impairment such as hemolysis and systemic vasculopathy. Trial Registration: ClinicalTrials.gov identifier: NCT00434902.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。